李 心,龚 珉,徐为人,汤立达.抗体药物的国内外市场动态[J].现代药物与临床,2012,27(3):185-191
抗体药物的国内外市场动态
Market dynamics of antibody drugs in both domestic and abroad
  
DOI:10.7501/j.issn.1674-5515.[year].[issue].[sequence]
中文关键词:  抗体药物  单抗  生物制药
英文关键词:antibody drugs  monoclonal antibodies  biopharmaceuticals
基金项目:
作者单位E-mail
李 心 天津药物研究院 天津市新药设计与发现重点实验室天津 300193 lixinguizhou@hotmail.com 
龚 珉 天津药物研究院 天津市新药设计与发现重点实验室天津 300193  
徐为人 天津药物研究院 天津市新药设计与发现重点实验室天津 300193 xuwr@tjipr.com 
汤立达 天津药物研究院 天津市新药设计与发现重点实验室天津 300193  
摘要点击次数: 1537
全文下载次数: 5140
中文摘要:
      生物制药是近年来医药行业中增长最迅速的行业之一,治疗性抗体作为生物药物中最耀眼的明珠已成为生物制药的最大产品类别,约占生物制药的35%。抗体药物在治疗以肿瘤为主的人类多种疾病方面起着重要作用。2011年,全球抗体药物的销售额达到480亿美元。我国当前正处在抗体药物快速发展阶段,目前SFDA共批准了17种单抗。预计到2015年,我国抗体销售额将达到325~650亿元。从产品来看,虽然我国已经有所突破,但数量和类型上,与国外的抗体药物还有很大差距。随着生物技术的不断发展,抗体药物的市场前景将会越来越广泛。
英文摘要:
      In recent years, biopharmaceuticals has become one of the fastest growing businesses in medicinal industry. Therapeutic antibody, accounting for about 35% of the biopharmaceuticals, has become the largest biopharmaceutical product category. Antibody drugs play an important effect in the treatment of a number of human diseases, especially in antitumor. In 2011, the global sales of antibody drugs have reached 48 billion dollar. Currently, China is in the initial stage of the rapid development of antibody drugs. At present, 17 kinds of monoclonal antibodies were approved by SFDA. In 2015, it is estimated that the sales of antibody drugs of China will be 32.5—65.0 billion Yuan. Although we had a breakthrough in antibody products, we still have a big gap compared with the developed countries in amounts and types. With the continuous development of biotechnology, the market prospects of antibody drugs will become more and more extensive.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 6064895 位访客
版权所有 天津中草药杂志社(天津市南开区鞍山西道308号 300193)
联系电话:022-23006823 传真:022-23006823 E_mail:dc@tiprpress.com
津备案:津ICP备13000267号 互联网药品信息服务资格证书编号:(津)-非经营性-2015-0031